MBX Biosciences, Inc. Income Statement
MBX / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| SG&A Expense | $10.8M | $6.8M |
| R&D Expense | $57.4M | $28.5M |
| Operating Income | -$68.2M | -$35.3M |
| Income Tax | $0 | $0 |
| Net Income | -$61.9M | -$32.6M |
| EPS (Basic) | -$5.82 | -$31.96 |
| EPS (Diluted) | -$5.82 | -$31.96 |
| Shares Outstanding | 10.6M | 1.0M |